• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Science 37 Holdings Inc. (Amendment)

    6/15/22 5:00:28 PM ET
    $SNCE
    Computer Software: Prepackaged Software
    Technology
    Get the next $SNCE alert in real time by email
    SC 13D/A 1 tm2218489d1_sc13da.htm SC 13D/A

     

     

     

    UNITED STATES

    SECURITIES & EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13D
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)
    *
    Science 37 Holdings, Inc.
    (Name of Issuer)
    Common Stock, $0.0001 par value per share
    (Title of Class of Securities)
    808644108
    (CUSIP Number)

    Redmile Group, LLC

    Attn: Jennifer Ciresi

    One Letterman Drive, Bldg D, Ste D3-300
    San Francisco, CA 94129

    (415) 489-9980

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    June 13, 2022

    (Date of Event Which Requires Filing of This Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 13d-7(b) for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No.: 808644108

     

    1. NAME OF REPORTING PERSON
      Redmile Group, LLC
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a)      ¨
      (b)     ¨
    3. SEC USE ONLY
       
    4. SOURCE OF FUNDS (SEE INSTRUCTIONS)
      OO
    5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
      ¨
    6. CITIZENSHIP OR PLACE OF ORGANIZATION
      Delaware
    NUMBER OF SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING PERSON
    WITH
    7. SOLE VOTING POWER
      0
    8. SHARED VOTING POWER
      19,808,234 (1)
    9. SOLE DISPOSITIVE POWER
      0
    10. SHARED DISPOSITIVE POWER
      19,808,234 (1)
    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      19,808,234 (1)
    12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
      17.1% (2)
    14. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      IA, OO

     

    -2-

     

     

    (1)  The Reporting Person may be deemed to beneficially own 19,808,234 shares of the common stock, $0.0001 par value per share (the “Common Stock”), of Science 37 Holdings, Inc., a Delaware corporation (the “Issuer”), held by certain private investment vehicles managed by Redmile Group, LLC (the “Redmile Funds”). Redmile Group, LLC (“Redmile”) is the investment manager/adviser to each of the Redmile Funds and, in such capacity, exercises sole voting and investment power over all of the shares held by the Redmile Funds and may be deemed to be the beneficial owner of these shares. Jeremy C. Green serves as the managing member of Redmile and also may be deemed to be the beneficial owner of these shares. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

     

    (2) Percent of class calculated based on 115,881,097 shares of Common Stock outstanding as of May 6, 2022, as disclosed in the Issuer’s Supplement No. 4 to the Prospectus dated April 20, 2022 as filed with the SEC on May 19, 2022 (the “Prospectus Supplement”).

      

    -3-

     

     

    CUSIP No.: 808644108

      

    1. NAME OF REPORTING PERSON
      Jeremy C. Green
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a)      ¨
      (b)     ¨
    3. SEC USE ONLY
       
    4. SOURCE OF FUNDS (SEE INSTRUCTIONS)
      OO
    5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
      ¨
    6. CITIZENSHIP OR PLACE OF ORGANIZATION
      United Kingdom
    NUMBER OF SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING PERSON
    WITH
    7. SOLE VOTING POWER
      0
    8. SHARED VOTING POWER
      19,808,234 (1)
    9. SOLE DISPOSITIVE POWER
      0
    10. SHARED DISPOSITIVE POWER
      19,808,234 (1)
    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      19,808,234 (1)
    12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
      17.1% (2)
    14. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      IN, HC

     

    -4-

     

     

    (1) The Reporting Person may be deemed to beneficially own 19,808,234 shares of Common Stock held by the Redmile Funds. Redmile is the investment manager/adviser to each of the Redmile Funds and, in such capacity, exercises sole voting and investment power over all of the shares held by the Redmile Funds and may be deemed to be the beneficial owner of these shares. Jeremy C. Green serves as the managing member of Redmile and also may be deemed to be the beneficial owner of these shares. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

     

    (2) Percent of class calculated based on 115,881,097 shares of Common Stock outstanding as of May 6, 2022, as disclosed in the Prospectus Supplement.

      

    -5-

     

     

    CUSIP No.: 808644108

     

    1. NAME OF REPORTING PERSON
      Redmile Private Investments II, L.P.
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a)      ¨
      (b)     ¨
    3. SEC USE ONLY
       
    4. SOURCE OF FUNDS (SEE INSTRUCTIONS)
      WC
    5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
      ¨
    6. CITIZENSHIP OR PLACE OF ORGANIZATION
      Delaware
    NUMBER OF SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING PERSON
    WITH
    7. SOLE VOTING POWER
      0
    8. SHARED VOTING POWER
      7,252,571
    9. SOLE DISPOSITIVE POWER
      0
    10. SHARED DISPOSITIVE POWER
      7,252,571
    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      7,252,571
    12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
      6.3% (1)
    14. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      PN

     

    (1) Percent of class calculated based on 115,881,097 shares of Common Stock outstanding as of May 6, 2022, as disclosed in the Prospectus Supplement.

     

    -6-

     

     

    CUSIP No.: 808644108

     

    1. NAME OF REPORTING PERSON
      RedCo II Master Fund, L.P.
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a)      ¨
      (b)     ¨
    3. SEC USE ONLY
       
    4. SOURCE OF FUNDS (SEE INSTRUCTIONS)
      WC
    5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
      ¨
    6. CITIZENSHIP OR PLACE OF ORGANIZATION
      Cayman Islands
    NUMBER OF SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING PERSON
    WITH
    7. SOLE VOTING POWER
      0
    8. SHARED VOTING POWER
     

    11,472,228

    9. SOLE DISPOSITIVE POWER
      0
    10. SHARED DISPOSITIVE POWER
     

    11,472,228

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     

    11,472,228

    12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
      9.9% (1)
    14. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      PN

     

    (1) Percent of class calculated based on 115,881,097 shares of Common Stock outstanding as of May 6, 2022, as disclosed in the Prospectus Supplement.

     

     -7- 

     

     

    This amendment No. 1 to Schedule 13D (this “Amendment”) amends and supplements the Schedule 13D filed with the SEC on October 18, 2021 (the “Prior Schedule 13D”), by Redmile Group, LLC, Jeremy C. Green, and Redmile Private Investments II, L.P., relating to the Common Stock of Science 37 Holdings, Inc., a Delaware corporation (the “Issuer”).

     

    ITEM 2.Identity and Background.

     

    Item 2 of the Prior Schedule 13D is hereby amended and restated in its entirety as follows:

     

    (a), (b), (c) and (f). This Schedule 13D is being filed jointly by Redmile Group, LLC, a Delaware limited liability company (“Redmile”), Jeremy C. Green, a citizen of the United Kingdom, Redmile Private Investments II, L.P., a Delaware limited partnership (“RPI II”), and Redco II Master Fund, L.P., a Cayman Islands limited partnership (“RedCo II” and collectively with RPI II, Redmile and Mr. Green, the “Reporting Persons”), pursuant to the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as separate persons and not as members of a group. See Exhibit 99.1 to this Schedule 13D for their Joint Filing Agreement.

     

    Redmile Group, LLC

     

    Redmile Group, LLC is a Delaware limited liability company whose principal business is to serve as investment manager/adviser to certain private investment funds and separately managed accounts, including the Redmile Funds. The business address of Redmile is One Letterman Drive, Bldg D, Ste D3-300, San Francisco, CA 94129. Information relating to the managing member of Redmile is set forth below.

     

    Jeremy C. Green

     

    The principal occupation of Jeremy C. Green is managing member of Redmile Group, LLC. The business address of Jeremy C. Green is c/o Redmile Group, LLC, One Letterman Drive, Bldg D, Ste D3-300, San Francisco, CA 94129. Jeremy C. Green is a citizen of the United Kingdom.

     

    Redmile Private Investments II, L.P.

     

    RPI II is a Delaware limited partnership whose principal business is to operate as a private investment fund. The business address of RPI II is One Letterman Drive, Bldg D, Ste D3-300, San Francisco, CA 94129. Redmile serves as the investment manager/adviser for RPI II. Information relating to Redmile and the managing member of Redmile is set forth above.

     

    RedCo II Master Fund, L.P.

     

    RedCo II is a Cayman Islands limited partnership whose principal business is to operate as a private investment fund. The business address of RedCo II is One Letterman Drive, Bldg D, Ste D3-300, San Francisco, CA 94129. Redmile serves as the investment manager/adviser for RedCo II. Information relating to Redmile and the managing member of Redmile is set forth above.

     

    (d) and (e). During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

     -8- 

     

     

    ITEM 3.Source and Amount of Funds or Other Consideration.

     

    The following sentence is hereby added after the last paragraph in Item 3 of the Prior Schedule 13D:

     

    On June 13, 2022, RedCo II completed cross trades with two other Redmile Funds using its working capital to acquire 6,472,228 shares of the Issuer’s Common Stock at a price of $3.38 per share. The transactions occurred simultaneously at no profit to the participating Redmile Funds and resulted in no change in the aggregate beneficial ownership of Redmile.

     

    ITEM 5.Interest in Securities of the Issuer.

     

    Item 5 of the Prior Schedule 13D is hereby amended and restated in its entirety as follows:

     

    (a) The aggregate amount of shares of Common Stock that may be deemed beneficially owned by the Reporting Persons is comprised of 19,808,234 shares of Common Stock held by the Redmile Funds (including (i) 7,252,571 shares of Common Stock held by RPI II, (ii) 467,380 shares of Common Stock held by RAF, L.P., (iii) 616,055 shares of Common Stock held by Redmile Strategic Master Fund, LP, and (v) 11,472,228 shares of Common Stock issued to RedCo II). Redmile is the investment manager/adviser to each of the Redmile Funds and, in such capacity, exercises sole voting and investment power over all of the shares held by the Redmile Funds and may be deemed to be the beneficial owner of these shares. Jeremy C. Green serves as the managing member of Redmile and also may be deemed to be the beneficial owner of these shares. Redmile and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

     

    For purposes of this Schedule 13D, the percent of class was calculated based on 115,881,097 shares of Common Stock outstanding as of May 6, 2022, as disclosed in the Prospectus Supplement.

     

    (b)          Redmile Group, LLC:

     

    (1) Sole Voting Power: 0

     

    (2) Shared Voting Power: 19,808,234

     

    (3) Sole Dispositive Power: 0

     

    (4) Shared Dispositive Power: 19,808,234

     

    Jeremy C. Green:

     

    (1) Sole Voting Power: 0

     

    (2) Shared Voting Power: 19,808,234

     

    (3) Sole Dispositive Power: 0

     

    (4) Shared Dispositive Power: 19,808,234

     

    Redmile Private Investments II, L.P.:

     

    (1) Sole Voting Power: 0

     

    (2) Shared Voting Power: 7,252,571

     

    (3) Sole Dispositive Power: 0

     

    (4) Shared Dispositive Power: 7,252,571

     

    RedCo II Master Fund, L.P.:

     

    (1) Sole Voting Power: 0

     

    (2) Shared Voting Power: 11,472,228

     

    (3) Sole Dispositive Power: 0

     

    (4) Shared Dispositive Power: 11,472,228

     

     -9- 

     

     

    (c) The information in Item 3 above relating to the transactions effected by the Reporting Persons in the Issuer’s Common Stock is incorporated herein by reference. No other transactions have been effected by the Reporting Persons during the past sixty days.

     

    (d) Not applicable.

     

    (e) Not applicable.

     

     -10- 

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: June 15, 2022 REDMILE GROUP, LLC
       
       
      /s/ Jeremy C. Green
      Name: Jeremy C. Green
      Title: Managing Member
       
       
    Dated: June 15, 2022 /s/ Jeremy C. Green
      JEREMY C. Green
       
       
    Dated: June 15, 2022 Redmile Private Investments II, L.P.
     

     

    By: Redmile PRIVATE Investments II (GP), LLC, its general partner

     

    By: REDMILE GROUP, LLC, its managing member

     

     

      /s/ Jeremy C. Green
      Name: Jeremy C. Green
      Title: Managing Member
       
       

    Dated: June 15, 2022

    RedCO II MASTER FUND, L.P.

     

     

    By: RedCo II (GP), LLC, its general partner

     

     

      /s/ Jeremy C. Green
      Name: Jeremy C. Green
      Title: Managing Member

     

     

    Get the next $SNCE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNCE

    DatePrice TargetRatingAnalyst
    11/1/2021$15.00Buy
    Lake Street
    11/1/2021$15.00Outperform
    Robert W. Baird
    11/1/2021Outperform
    William Blair
    11/1/2021$15.00Outperform
    Baird
    10/22/2021$14.00Outperform
    Cowen & Co.
    More analyst ratings

    $SNCE
    SEC Filings

    See more
    • SEC Form 15-12G filed by Science 37 Holdings Inc.

      15-12G - Science 37 Holdings, Inc. (0001819113) (Filer)

      3/22/24 6:50:27 PM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • SEC Form EFFECT filed by Science 37 Holdings Inc.

      EFFECT - Science 37 Holdings, Inc. (0001819113) (Filer)

      3/15/24 12:15:04 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • SEC Form EFFECT filed by Science 37 Holdings Inc.

      EFFECT - Science 37 Holdings, Inc. (0001819113) (Filer)

      3/15/24 12:15:11 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology

    $SNCE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial

      MORRISVILLE, N.C., April 08, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, today announced the successful completion of its second FDA inspection, reaffirming the quality of its Direct-to-Patient Site for clinical research. The inspection resulted in a No Action Indicated (NAI) categorization, with no objectionable conditions noted and no Form 483 issued. Led by Science 37's internal Quality Assurance & Compliance team, the inspection focused on the company's role in a registrational Phase 3 asthma study, which Science 37 contributed 28% of the total patient enrollment. The FDA evaluated internal processes, technology, data integrity, patien

      4/8/25 8:00:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

      MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company's Chief Commercial Officer, Van Horn's appointment follows his pivotal role in driving operational excellence and shaping the company's strategic direction to better prioritize client success – initiatives credited with driving growth for the company. Since joining Science 37 in 2021, Van Horn has been a chief architect in assembling and empowering a team capable of matching or surpassing the testing standards and data quality of traditional clinical trial sites. By emphasizing

      1/14/25 8:00:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial

      MORRISVILLE, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by global biopharmaceutical company, GSK. The hepatology study of an investigational medicine for cholestatic pruritus in primary biliary cholangitis (PBC) required 230 global participants, of which Science 37 was able to contribute almost half (17 - 47%) of the U.S. enrollment for the study. Recognizing that the available participant population for rare disease studies is often extremely limited and dispersed globally, GSK welcomed an innovative approach to expanding trial

      11/21/24 8:00:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology

    $SNCE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Science 37 Holdings Inc. (Amendment)

      SC 13D/A - Science 37 Holdings, Inc. (0001819113) (Subject)

      3/14/24 4:17:56 PM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13D/A filed by Science 37 Holdings Inc. (Amendment)

      SC 13D/A - Science 37 Holdings, Inc. (0001819113) (Subject)

      3/13/24 5:15:52 PM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13D/A filed by Science 37 Holdings Inc. (Amendment)

      SC 13D/A - Science 37 Holdings, Inc. (0001819113) (Subject)

      1/31/24 5:15:22 PM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology

    $SNCE
    Leadership Updates

    Live Leadership Updates

    See more
    • Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

      MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company's Chief Commercial Officer, Van Horn's appointment follows his pivotal role in driving operational excellence and shaping the company's strategic direction to better prioritize client success – initiatives credited with driving growth for the company. Since joining Science 37 in 2021, Van Horn has been a chief architect in assembling and empowering a team capable of matching or surpassing the testing standards and data quality of traditional clinical trial sites. By emphasizing

      1/14/25 8:00:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Science 37 Appoints SVP, Erica Prowisor, to Bolster Patient Recruitment Velocity, Diversity

      RESEARCH TRIANGLE PARK, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™, announced today Erica Prowisor as SVP of Patient and Provider Networks to accelerate patient recruitment, ensure participant diversity and gain operational efficiencies. Erica has been forging new ground as a leader in patient recruitment for nearly 20 years, most notably with IQVIA where she was Global Head of Recruitment and Retention for more than three years and led the company's direct-to-patient recruitment and retention efforts. Prior to IQVIA, Erica spent 11 years with Acurian through the acquisition by PPD where she was Head of Enrollment Opera

      4/25/23 7:59:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Science 37 Adds New Head of Quality, Irena Lambridis

      RESEARCH TRIANGLE PARK, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™, today announced the appointment of Irena Lambridis as its Global Head of Quality Assurance & Compliance. Irena will be responsible for overseeing quality and compliance across all functions, including the Company's newly announced global Centers of Excellence in India, Pakistan, and Slovakia. This key appointment reflects Science 37's commitment to quality as it expands operations globally. Irena brings nearly two decades of experience in clinical research quality assurance, having held senior leadership positions at KCR and Novella Clinical (now IQVIA

      4/18/23 7:59:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology

    $SNCE
    Financials

    Live finance-specific insights

    See more
    • Science 37 Reports Third Quarter 2023 Financial Results

      RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), ("Science 37"), the industry-leading Metasite™, today reported its financial results for the quarter ended September 30, 2023. "Our third quarter results were highlighted by continued quarterly improvements in our key profitability metrics and cash burn rate," stated David Coman, Chief Executive Officer of Science 37. "We look forward to a strong finish to the year and positive momentum headed into 2024." Quarterly Financial Highlights Gross bookings were $17.9 million for the quarter ended September 30, 2023, a 50.6%

      11/7/23 6:00:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Science 37 to Report Third Quarter 2023 Financial Results on November 7, 2023

      RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™ today announced it will report third quarter 2023 financial results prior to the market open on Tuesday, November 7, 2023. The Science 37 management team will host a conference call to discuss these results on November 7, 2023, at 8:30 a.m. Eastern Time. The call can be accessed by dialing 1-877-269-7751 (toll-free domestic) or 1-201-389-0908 (international) and using the Conference ID 13741458 or by utilizing the Call me™ feature using this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the i

      10/24/23 6:00:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Science 37 Reports Second Quarter 2023 Financial Results

      RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), ("Science 37"), the industry-leading Metasite™, today reported its financial results for the quarter ended June 30, 2023. "The actions we have taken over the past nine months are leading to meaningful improvements as evidenced by our sequential quarterly results including growth in gross bookings and gross profit margins along with a reduction in cash burn," stated David Coman, Chief Executive Officer of Science 37. "We look forward to finishing the year strong and continuing to position the company for sustainable financial growth and shareholder value creation." Quarterly Financial

      8/8/23 6:00:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology

    $SNCE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SNCE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 4 filed by Thermo Fisher Scientific Inc.

      4 - Science 37 Holdings, Inc. (0001819113) (Issuer)

      3/14/24 4:26:37 PM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by Thermo Fisher Scientific Inc.

      4 - Science 37 Holdings, Inc. (0001819113) (Issuer)

      3/14/24 4:25:33 PM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • New insider Thermo Fisher Scientific Inc. claimed ownership of 17,379,797 shares (SEC Form 3) (Amendment)

      3/A - Science 37 Holdings, Inc. (0001819113) (Issuer)

      3/14/24 4:20:09 PM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Lake Street initiated coverage on Science 37 with a new price target

      Lake Street initiated coverage of Science 37 with a rating of Buy and set a new price target of $15.00

      11/1/21 9:12:40 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Robert W. Baird initiated coverage on Science 37 with a new price target

      Robert W. Baird initiated coverage of Science 37 with a rating of Outperform and set a new price target of $15.00

      11/1/21 7:43:34 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • William Blair initiated coverage on Science 37 Hldgs

      William Blair initiated coverage of Science 37 Hldgs with a rating of Outperform

      11/1/21 5:42:17 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology